Start-Up Quarterly Statistics, Q2 2015
This article was originally published in Start Up
Life sciences start-ups raised $2.61 billion in Q2 2015. Biotechs penned 38 alliances; seven acquisitions were signed, none in the medical device industry.
You may also be interested in...
GSK/Avalon Incubator Launches New Firms For Cardiac, Cancer, Lysosomal Storage Disorders
The partnership between GSK and Avalon has now launched six new biotechs in just over two years, each housed at Avalon’s incubator space in San Diego.
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
Deals In Depth: February 2023
Two $1bn+ alliances were penned in February. Topping the list was a potential $1.16bn deal between AstraZeneca and KYM Biosciences (a joint venture company of Keymed Biosciences and Lepu Biopharma, of which Keymed owns 70%). Under the exclusive global agreement, AstraZeneca will develop, manufacture and commercialize CMG901, a Phase I antibody drug conjugate for the treatment of Claudin 18.2-positive solid tumors including gastric cancers.